bioAffinity Technologies: Advancing Non-Invasive Cancer Detection and Therapy

bioAffinity Technologies, Inc., a San Antonio-based biotech firm, is dedicated to pioneering advancements in cancer diagnostics and treatment. Established in 2014, the company focuses on developing innovative, non-invasive solutions aimed at identifying cancer in its earliest stages—when treatment is most effective.

As a development-stage enterprise, bioAffinity is actively engaged in creating in-vitro diagnostic tests and cancer therapies that specifically target malignant cells. Their approach utilizes proprietary technology designed to distinguish cancerous cells from healthy ones, offering a more precise and less invasive method of detection compared to traditional diagnostic procedures.

One of the company’s core objectives is to fill the critical gap in early cancer diagnosis. Many types of cancer remain undetected until they reach advanced stages, significantly reducing treatment options and survival rates. By emphasizing early detection through laboratory-developed tests, bioAffinity aims to shift the paradigm in cancer care and improve patient outcomes.

In addition to diagnostics, the company is exploring targeted therapeutic solutions. These treatments are engineered to selectively impact cancer cells, minimizing damage to healthy tissues—a common drawback in conventional cancer therapies such as chemotherapy or radiation. This selective approach not only improves the safety profile of treatments but also enhances their overall efficacy.

Though still in the early phases of development, bioAffinity Technologies has positioned itself as a forward-thinking player in the life sciences sector. With a strong focus on research and innovation, the company seeks to provide tools that empower healthcare professionals and offer patients better, earlier, and safer options in the fight against cancer.

Headquartered in Texas, bioAffinity continues to build upon its foundational mission: to transform cancer diagnostics and therapeutics through cutting-edge science and a commitment to improving lives.